Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference

BETHESDA, Md., July 05, 2007 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, Inc., will present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference in New York on Thursday, July 12, 2007 at 10:00am, eastern.

A webcast of Dr. Itin's remarks will be available live. You can access the webcast at: www.micromet-inc.com. An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet's novel BiTE(R) product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, widely recognized as the most powerful 'killer cells' of the human immune system. Adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. Micromet has established collaborations with MedImmune, Inc. for MT103/MEDI-538, Merck Serono for adecatumumab (MT201), and Nycomed for MT203.

CONTACT: Christopher Schnittker, SVP & CFO, of Micromet, Inc.,+1-240-752-1421, ; or Investors: Susan Noonan,+1-212-966-3650, ; or Media: Patricia Garrison,+1-917-322-2567, , both for Micromet, Inc. cschnittker@micromet-inc.com susan@sanoonan.com pgarrison@rxir.com

Web site: http://www.micromet-inc.com/

Ticker Symbol: (NASDAQ-NMS:MITI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: July 2007

View comments

Hide
(web2)